» Articles » PMID: 18829533

Brn-2 Represses Microphthalmia-associated Transcription Factor Expression and Marks a Distinct Subpopulation of Microphthalmia-associated Transcription Factor-negative Melanoma Cells

Overview
Journal Cancer Res
Specialty Oncology
Date 2008 Oct 3
PMID 18829533
Citations 96
Authors
Affiliations
Soon will be listed here.
Abstract

The origin of tumor heterogeneity is poorly understood, yet it represents a major barrier to effective therapy. In melanoma and in melanocyte development, the microphthalmia-associated transcription factor (Mitf) controls survival, differentiation, proliferation, and migration/metastasis. The Brn-2 (N-Oct-3, POU3F2) transcription factor also regulates melanoma proliferation and is up-regulated by BRAF and beta-catenin, two key melanoma-associated signaling molecules. Here, we show that Brn-2 also regulates invasiveness and directly represses Mitf expression. Remarkably, in melanoma biopsies, Mitf and Brn-2 each mark a distinct subpopulation of melanoma cells, providing a striking illustration of melanoma tumor heterogeneity with implications for melanoma therapy.

Citing Articles

Melanocyte lineage dynamics in development, growth and disease.

Brombin A, Patton E Development. 2024; 151(15).

PMID: 39092608 PMC: 11317096. DOI: 10.1242/dev.201266.


Transcription factor activating enhancer-binding protein 2ε (AP2ε) modulates phenotypic plasticity and progression of malignant melanoma.

Staebler S, Rottensteiner-Brandl U, El Ahmad Z, Kappelmann-Fenzl M, Arkudas A, Kengelbach-Weigand A Cell Death Dis. 2024; 15(5):351.

PMID: 38773108 PMC: 11109141. DOI: 10.1038/s41419-024-06733-3.


Thiol starvation triggers melanoma state switching in an ATF4 and NRF2-dependent manner.

Meinert M, Jessen C, Hufnagel A, Charlotte Kress J, Burnworth M, Daubler T Redox Biol. 2024; 70:103011.

PMID: 38219574 PMC: 10825660. DOI: 10.1016/j.redox.2023.103011.


Exploring the Complex and Multifaceted Interplay between Melanoma Cells and the Tumor Microenvironment.

Kuras M Int J Mol Sci. 2023; 24(18).

PMID: 37762707 PMC: 10531837. DOI: 10.3390/ijms241814403.


Therapeutic targeting of anoikis resistance in cutaneous melanoma metastasis.

Neuendorf H, Simmons J, Boyle G Front Cell Dev Biol. 2023; 11:1183328.

PMID: 37181747 PMC: 10169659. DOI: 10.3389/fcell.2023.1183328.